Here are nine things to know from the report.
• Linaclotide in IBS-C. AGA recommends use (strong recommendation, high-quality evidence).
• Lubiprostone in IBS-C. AGA suggests use (conditional recommendation, moderate-quality evidence).
• PEG laxatives in IBS-C. AGA suggests use (conditional recommendation, low-quality evidence).
• Rifaximin in IBS-D. AGA suggests use (conditional recommendation, moderate-quality evidence).
• Alosetron in IBS-D. AGA suggests use (conditional recommendation, moderate-quality evidence).
• Loperamide in IBS-D. AGA suggests use (conditional recommendation, very low-quality evidence).
• Tricyclic antidepressants in IBS. AGA suggests use (conditional recommendation, low-quality evidence).
• Selective serotonin reuptake inhibitors in IBS. AGA suggests use (conditional recommendation, low-quality evidence).
• Antispasmodics in IBS. AGA suggests use (conditional recommendation, low-quality evidence).
More articles on gastroenterology:
7 professional GI society updates
Beyond proceduralism for practice improvement: 3 gastroenterologists’ best ideas
4 must-reads on Crohn’s disease
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
